Thomas Lynch was appointed as Director at Natera, Inc..
“appointed Thomas Lynch as a member of the Board, in each case effective as of June 2, 2026.”
Natera, Inc. — fact timeline
Source-grounded facts extracted from Natera, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Natera, Inc. shareholders approved Approval of an amendment to the Amended and Restated 2015 Equity Incentive Plan at the 2026-06-11 meeting.
“Proposal 5 : The approval of an amendment to the Amended and Restated 2015 Equity Incentive Plan: For Against Abstentions Broker Non-Votes 95,735,506 26,861,815 123,232 7,970,544”
Natera, Inc. shareholders approved Advisory vote on the frequency of the advisory vote on the compensation of the Company’s named executive officers at the 2026-06-11 meeting.
“Proposal 4 : The advisory vote on the frequency of the advisory vote on the compensation of the Company’s named executive officers: One Year Two Years Three Years Abstain 121,647,012 36,823 972,982 63,736”
Natera, Inc. shareholders approved Advisory vote on the compensation of the Company’s named executive officers at the 2026-06-11 meeting.
“Proposal 3 : The advisory vote on the compensation of the Company’s named executive officers: For Against Abstentions Broker Non-Votes 119,883,700 2,492,978 343,875 7,970,544”
Natera, Inc. shareholders approved Ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 at the 2026-06-11 meeting.
“Proposal 2 : The ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026: For Against Abstentions Broker Non-Votes 129,786,351 848,088 56,658 0”
Natera, Inc. shareholders approved Election of three Class II directors to serve until the 2029 annual meeting and one Class I director to serve until the 2028 annual meeting at the 2026-06-11 meeting.
“Proposal 1 : The election of three directors to serve as Class II directors until the 2029 annual meeting of stockholders, and the election of one director to serve as a Class I director until the 2028 annual meeting of stockholders, or until his or her successor is duly elected and qualified: Name of Class II Nominee For Withheld Broker Non-Votes Rowan Chapman 106,832,026 15,888,527 7,970,544 Herm Rosenman 103,920,050 18,800,503 7,970,544 Jonathan Sheena 106,940,124 15,780,429 7,970,544 Name of Class I Nominee For Withheld Broker Non-Votes Eric H. Rubin 120,601,658 2,118,895 7,970,544”
Thomas Lynch was appointed as Director at Natera, Inc..
“appointed Thomas Lynch as a member of the Board, in each case effective as of June 2, 2026.”
Natera, Inc. reported first quarter ended March 31, 2026 results: revenue $696.6 million, net income $85.1 million, EPS ($0.60) per diluted share. Guidance raised.
“in cell-free DNA and genetic testing, today reported its financial results for the first quarter ended March 31, 2026. Recent Financial Highlights • Generated total revenues of $696.6 million in the first quarter of 2026, compared to $501.8 million in the first quarter of 2025, an increase of 38.8%. • Generated a gross margin 1 of 64.7% in the first quarter of 2026,”
Monica Bertagnolli was appointed as member of the Board at Natera, Inc..
“appointed Monica Bertagnolli as a member of the Board, in each case effective as of March 6, 2025.”
Natera, Inc. reported first quarter ended March 31, 2024 results: revenue $367.7 million, net income net loss of $67.6 million, EPS ($0.56) per diluted share.
“First Quarter Ended March 31, 2024 Financial Results Total revenues were $367.7 million in the first quarter of 2024 compared to $241.8 million in the first quarter of 2023, an increase of 52.1%. The increase in total revenues was driven primarily by a 53.4% increase in product revenues, which were $364.7 million in the first quarter of 2024 compared to $237.8 million in the first quarter of 2023. The increase in product revenues was primarily driven by an increase in volume, as well as average selling price improvements. Natera processed approximately 735,800 tests in the first quarter of 2024, including approximately 718,700 tests accessioned in its laboratory, compared to approximately 626,200 tests processed, including approximately 607,700 tests accessioned in its laboratory, in the first quarter of 2023. In the first quarter of 2024, Natera recognized revenue on approximately 679,400 tests for which results were reported to customers in the period (tests reported), including appr”
Natera, Inc. reported fourth quarter and year ended December 31, 2023 results: revenue $311.1 million, net income ($0.65) per diluted share, EPS ($0.65) per diluted share.
“testing , today reported its financial results for the fourth quarter and year ended December 31, 2023. Recent Strategic and Financial Highlights ● Generated total revenues of $311.1 million in the fourth quarter of 2023, compared to $217.3 million in the fourth quarter of 2022, an increase of 43.2%. Product revenues grew 44.3% over the same period. ● Generated total”
Natera, Inc. reported fourth quarter and fiscal year ended December 31, 2023 results: revenue approximately $300 million in the fourth quarter of 2023.
“Natera, Inc. (the “Company”) issued a press release announcing preliminary revenue results for its fourth quarter and fiscal year ended December 31, 2023.”
Natera, Inc. reported third quarter ended September 30, 2023 results: revenue $268.3 million, net income net loss of $109.0 million, EPS ($0.95) per diluted share. Guidance raised.
“cell-free DNA testing , today reported financial results for the third quarter ended September 30, 2023. Recent Strategic and Financial Highlights ● Generated total revenues of $268.3 million in the third quarter of 2023, compared to $210.6 million in the third quarter of 2022, an increase of approximately 27%. Product revenues grew approximately 33% over the same”
Natera, Inc. entered into Underwriting Agreement with Morgan Stanley & Co. LLC, Goldman Sachs & Co. LLC, Cowen and Company, LLC and Piper Sandler & Co., as representatives of the several underwriters valued at $235.4 million (effective 2023-09-06).
“On September 6, 2023, Natera, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Morgan Stanley & Co. LLC, Goldman Sachs & Co. LLC, Cowen and Company, LLC and Piper Sandler & Co., as representatives of the several underwriters named in Schedule I thereto (the “Underwriters”), in connection with the offer and sale by the Company of 4,550,000 shares of common stock of the Company, par value $0.0001 per share, at a price to the public of $55.00 per share.”
Natera, Inc. reported the second quarter ended June 30, 2023 results: revenue $261.4 million, net income $110.8 million, EPS ($0.97) per diluted share. Guidance raised.
“in cell-free DNA testing , today reported financial results for the second quarter ended June 30, 2023. Recent Strategic and Financial Highlights ● Generated total revenues of $261.4 million in the second quarter of 2023, compared to $198.2 million in the second quarter of 2022, an increase of 31.9%. Product revenues grew 32.7% over the same period. ● Processed”
Natera, Inc. shareholders approved Advisory vote on compensation of named executive officers at the 2023-06-09 meeting.
“Proposal 3 : The advisory vote on the compensation of Natera’s named executive officers: For Against Abstentions Broker Non-Votes 88,588,552 4,729,453 86,259 11,899,430”
Natera, Inc. shareholders approved Ratification of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-06-09 meeting.
“Proposal 2 : The ratification of the appointment of Ernst & Young LLP as Natera’s independent registered public accounting firm for the fiscal year ending December 31, 2023: For Against Abstentions Broker Non-Votes 104,893,902 361,715 48,077 0”
Natera, Inc. reported first quarter ended March 31, 2023 results: revenue $241.8 million, net income net loss of $136.9 million, EPS ($1.23) per diluted share. Guidance raised.
“in cell-free DNA testing , today reported financial results for the first quarter ended March 31, 2023. Recent Strategic and Financial Highlights ● Generated total revenues of $241.8 million in the first quarter of 2023, compared to $194.1 million in the first quarter of 2022, an increase of 24.5%. Product revenues grew 25.2% over the same period. ● Processed”
Ruth Williams-Brinkley was appointed as Director at Natera, Inc..
“appointed Ruth Williams-Brinkley as a member of the Board, in each case effective as of March 2, 2023.”
Natera, Inc. entered into Underwriting Agreement with Morgan Stanley & Co. LLC, Cowen and Company, LLC, and SVB Securities LLC, as representatives valued at approximately $376.6 million (effective 2022-11-15).
“On November 15, 2022, Natera, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Morgan Stanley & Co. LLC, Cowen and Company, LLC, and SVB Securities LLC, as representatives (the “Representatives”) of the several underwriters named in Schedule I thereto (the “Underwriters”), in connection with the offer and sale by the Company of 11,430,000 shares of common stock of the Company, par value $0.0001 per share, at a price to the public of $35.00 per share.”
Natera, Inc. reported third quarter ended September 30, 2022 results: revenue $210.6 million, net income net loss of $121.5 million, EPS ($1.25) per diluted share. Guidance raised.
“Third Quarter Ended September 30, 2022 Financial Results Total revenues were $210.6 million in the third quarter of 2022 compared to $158.1 million for the third quarter of 2021, an increase of 33.2%. Product revenues were $199.8 million in the third quarter of 2022 compared to $153.9 million in the third quarter of 2021, an increase of 29.8%. The growth in product revenues was driven by an increase in test volumes compared to the third quarter of 2021. Natera processed approximately 517,500 tests in the third quarter of 2022, including approximately 502,900 tests accessioned in its laboratory. This compares to approximately 407,300 tests processed in the third quarter of 2021, including approximately 394,200 tests accessioned in its laboratory, an increase of 27.1% for the quarter. In the three months ended September 30, 2022, Natera recognized revenue on approximately 483,000 tests for which results were reported to customers in the period (tests reported), including approximately 46”
Monica Bertagnolli resigned as Director at Natera, Inc..
“On August 11, 2022, Monica Bertagnolli notified the Board of Directors (the “Board”) of Natera, Inc. (“Natera” or the “Company”) of her intention to resign as a member of the Board and any committees of the Board, effective August 12, 2022, in connection with her appointment as Director of the National Cancer Institute.”
Todd Cozzens resigned as member of the Board at Natera, Inc..
“On April 8, 2022, Todd Cozzens notified the Board of Directors (the “Board”) of Natera, Inc. (“Natera” or the “Company”) of his intention to resign as a member of the Board and any committees of the Board, effective May 25, 2022.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.